Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M, Cafferkey C, Goode EF, Kouvelakis K, Hughes D, Reguera P, Kalaitzaki E, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N. Davidson M, et al. Among authors: kalaitzaki e. Clin Colorectal Cancer. 2018 Sep;17(3):223-230. doi: 10.1016/j.clcc.2018.05.014. Epub 2018 Jun 8. Clin Colorectal Cancer. 2018. PMID: 29980492
Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.
Khan K, Athauda A, Aitken K, Cunningham D, Watkins D, Starling N, Cook GJ, Kalaitzaki E, Chau I, Rao S. Khan K, et al. Among authors: kalaitzaki e. Oncologist. 2016 Dec;21(12):1502-1508. doi: 10.1634/theoncologist.2016-0222. Epub 2016 Oct 14. Oncologist. 2016. PMID: 27742904 Free PMC article.
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, Morano F, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I. Sclafani F, et al. Among authors: kalaitzaki e. Oncologist. 2017 Jun;22(6):728-736. doi: 10.1634/theoncologist.2016-0396. Epub 2017 May 5. Oncologist. 2017. PMID: 28476941 Free PMC article. Clinical Trial.
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I. Khan K, et al. Among authors: kalaitzaki e. Clin Colorectal Cancer. 2019 Mar;18(1):64-71.e1. doi: 10.1016/j.clcc.2018.09.010. Epub 2018 Sep 29. Clin Colorectal Cancer. 2019. PMID: 30404764
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I. Sclafani F, et al. Among authors: kalaitzaki e. Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5. Int J Cancer. 2020. PMID: 31199501 Free article. Clinical Trial.
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
Khakoo S, Carter PD, Brown G, Valeri N, Picchia S, Bali MA, Shaikh R, Jones T, Begum R, Rana I, Wotherspoon A, Terlizzo M, von Loga K, Kalaitzaki E, Saffery C, Watkins D, Tait D, Chau I, Starling N, Hubank M, Cunningham D. Khakoo S, et al. Among authors: kalaitzaki e. Clin Cancer Res. 2020 Jan 1;26(1):183-192. doi: 10.1158/1078-0432.CCR-19-1996. Epub 2019 Dec 18. Clin Cancer Res. 2020. PMID: 31852830
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
Lau D, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F, Smith G, Begum R, Crux R, Gillbanks A, Wordsworth S, Chau I, Starling N, Cunningham D, Dhillon T. Lau D, et al. Among authors: kalaitzaki e. ESMO Open. 2020 Feb;5(1):e000638. doi: 10.1136/esmoopen-2019-000638. ESMO Open. 2020. PMID: 32079623 Free PMC article. Clinical Trial.
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.
Turkes F, Bryant A, Begum R, Davidson M, Kalaitzaki E, Aresu M, Lazaro-Alcausi R, Bryant J, Rana I, Chua S, Aronson L, Hulkki-Wilson S, Fribbens C, Watkins D, Rao S, Starling N, Cunningham D, Chong IY, Chau I. Turkes F, et al. Among authors: kalaitzaki e. Curr Oncol. 2022 Mar 22;29(4):2174-2184. doi: 10.3390/curroncol29040176. Curr Oncol. 2022. PMID: 35448150 Free PMC article.
33 results